Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile

Bone Marrow Transplantation

Volumn 18, Issue 3, 1996, Pages 633-636

  Goldberg, S L ^a,b   Shubert, J ^a   Rao, A K ^a   Redei, I ^a   Klumpp, T R ^a   Mangan, K F ^a  

^a Temple University Health Sciences Center   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Bone marrow transplantation; Coagulation; Tissue plasminogen activator; Veno occlusive disease

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; HEPARIN; PROTEIN C; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN K GROUP;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CLOTTING; BOLUS INJECTION; CASE REPORT; CONTINUOUS INFUSION; DRUG EFFICACY; FIBRINOLYSIS; HEMOSTASIS; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER VEIN OBSTRUCTION; MALE; PRIORITY JOURNAL;

ADOLESCENT; BLOOD COAGULATION; BONE MARROW TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029792765     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 1995; 85: 3005-3020.
3. McDonald GB, Hinds M, Fisher L et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
4. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-558.
5. Rio B, Andreu G, Nicod A et al. Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67: 1773-1776.
6. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5: 439-441.
7. Gertler JP, Abbott WM. Prothrombotic and fibrinolytic function of normal and perturbed endothelium. J Surg Res 1992; 52: 89-95.
8. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75: 329-336.
9. Collins PW, Gutteridge CN, O'Driscoll A et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992; 10: 499-506.
10. Catani L, Gugliotta L, Belmonte MM et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant 1993; 12: 253-259.
11. Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
12. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-3462.
13. Scrobohci ML, Drouet L, Monem-Mansi A et al. Liver veno-occlusive disease after bone marrow transplantation: changes in coagulation parameters and endothelial markers. Thromb Res 1991; 63: 509-519.
14. Haire WD, Gordon BG, Stephens L, Comp PC. Protein C (PC) deficiency during marrow transplantation: a frequent occurrence associated with a decrease in PC antigen and production of a dysfunctional PC molecule. Blood 1991; 78 (Suppl. 1): 288a.
15. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin III and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 8: 497-502.
16. Klumpp TR, Herman JH, Ennis S et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 17: 1035-1041.
17. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
18. Laporte JPh, Lesage S, Tilleul P et al. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. Lancet 1992; 339: 1057.
19. Rosti G, Bandini G, Belardinelli A et al. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. Lancet 1992; 339: 1481-1482.
20. Ringden O, Wennberg L, Ericzon BG et al. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. Lancet 1992; 340: 546-547.
21. Yu LC, Malhani I, Regueira O et al. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.